Human Genome Sciences

(HGSI)

said Japan's

Takeda Chemicals

has selected about 100 individual drug discovery targets that the company will use in its small-molecule and antibody drug discovery research.

Human Genome, a gene researching company, said many of the targets are in the realm of Takeda's therapeutic areas, such as diabetes, cardiovascular disease, bone and joint diseases, central nervous system disorders and allergies.

The deal entitles Human Genome Sciences to receive milestone and royalty payments on products developed and commercialized by Takeda. Pharmaceuticals company Takeda is one of Human Genome's five strategic partners in the human gene consortium.

Shares of Human Genome Sciences, which is based in Rockville, Md., rose $3.06, or 7%, to $46.75 in recent

Nasdaq

trading.